Home » Topics » Disease categories and therapies » Urology

Urology
RSS

Urovant Sciences launches international phase III COURAGE study of vibegron

March 28, 2019

New mutations in NPHP3 and NEK8 are associated with renal-hepatic-pancreatic dysplasia

March 26, 2019

Positive topline results presented from pivotal phase III EMPOWUR study of vibegron

March 20, 2019

Arch Biopartners receives approval for phase I study of Metablok in Australia

March 20, 2019

Clinical data reported for litoxetine in mixed urinary incontinence

March 19, 2019

Veverimer phase III results for metabolic acidosis associated with chronic kidney disease

March 15, 2019

Dicerna enrolling in phase II study of DCR-PHXC for primary hyperoxaluria

March 11, 2019

Eli Lilly and Company synthesizes PDE1 inhibitors

March 4, 2019

Lilly synthesizes new phosphodiesterase PDE1 inhibitors

Feb. 26, 2019

Imarikiren improves albuminuria in patients with type 2 diabetes

Feb. 22, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 21, 2026.
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
News in brief
BioWorld Asia
BioWorld Asia briefs for May 19, 2026
WHO declares Ebola outbreak a public health emergency of international concern
BioWorld
The threat posed by the Ebola outbreak in the Democratic Republic of Congo has intensified, with the confirmation that it is caused by the Bundibugyo species of...
Nxera Pharma prepares and tests new GPR17 antagonists
BioWorld Science
Nxera Pharma UK Ltd. has identified new uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-Like) antagonists potentially useful for the treatment of...